Back to search

Article

β2-adrenoceptor activation enhances pyridostigmine efficacy in presynaptic congenital myasthenic syndrome

2026-05-12

Abstract excerpt

<b>Background and Purpose</b> Congenital myasthenic syndromes (CMS) are inherited disorders of neuromuscular transmission characterized by lifelong muscle weakness and fatigability. Variants in <i>SLC18A3</i>, encoding the vesicular acetylcholine transporter (VAChT), cause a severe presynaptic CMS with limited treatment options. Acetylcholinesterase inhibitors such as pyridostigmine are first-line therapy but ofte...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
05e42a64-1510-5f13-ae05-6f048d3bc71e
DOI
10.22541/authorea.15003132/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
β2-adrenoceptor activation enhances pyridostigmine efficacy in presynaptic congenital myasthenic syndromeDOI 10.22541/authorea.15003132/v1
Select a neighboring publication to make it the new centre.